BioMarin Pharmaceutical Return on Equity

BioMarin Pharmaceutical (BM8.F) currently reports a ROE of 1.15%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore BioMarin Pharmaceutical's ROE history and peer comparisons.

BioMarin Pharmaceutical's ROE of 1.15% is higher than the Healthcare sector average of -75.59%. That is roughly 101.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but BioMarin Pharmaceutical's current 1.15% should be judged against Healthcare norms (sector average: -75.59%) and against BM8.F's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 1.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for BioMarin Pharmaceutical, and consider following BM8.F for alerts when major investors trade the stock.

BioMarin Pharmaceutical is classified in the Healthcare sector. On ROE, it currently shows 1.15% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BM8.F with unrelated industries.